DNA methylation alterations in urothelial carcinoma

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 993-1001

  Neuhausen, Anne ^a   Florl, Andrea R ^a   Grimm, Marc Oliver ^a   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

5 aza deoxycytidine; Bladder cancer; Cancer classification; HDAC inhibitor; Hypermethylation; Hypomethylation; LINE 1; MS PCR; Prostate cancer; SFRP1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE 2 INHIBITOR; DEATH ASSOCIATED PROTEIN KINASE; DEATH ASSOCIATED PROTEIN KINASE 1; FRIZZLED PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN CDKN2A; PROTEIN SFRP1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROSTATE CANCER; SOUTHERN BLOTTING; UROGENITAL TRACT CANCER;

EID: 33751186134     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.2885     Document Type: Article

References (45)

1. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28.
2. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3:253-66.
3. Issa JP. CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 2000; 249:101-18.
4. Schulz WA. Qualified promise: DNA methylation assays for cancer detection and classification (editorial). J Biomed Biotechnol 2005; 3:227-9.
5. Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, Engers R, Ackermann R, Schulz WA. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91:985-94.
6. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202:233-40.
7. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975-86.
8. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC, von Ruecker A. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11:4097-106.
9. Salem C, Liang G, Tsai YC, Coulter J, Knowles MA, Feng AC, Groshen S, Nichols PW, Jones PA. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000; 60:2473-6.
10. Markl IDC, Cheng J, Liang G, Shibata D, Laird PW, Jones PA. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 2001; 61:5875-84.
11. Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zochbauer-Muller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61:8659-63.
12. Chan MWY, Chan LW, Tang NLS, Tong JHM, Lo KW, Lee TL, Cheung HY, Wong WS, Chan PS, Lai FM, To KF. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8:464-70.
13. Tada Y, Wada M, Taguchi KI, Mochida Y, Kinugawa N, Tsuneyoshi M, Naito S, Kuwano M. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancer. Cancer Res 2002; 62:4048-53.
14. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004; 10:1887-93.
15. Friedrich MG, Weisenberger DJ, Cheng JC, Chandrasoma S, Siegmund KD, Gonzalgo ML, Huland H, Jones PA, Liang G. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res 2004; 10:7457-65.
16. Catto JWF, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, Fromont G, Sibony M, Cussenot O, Meuth M, Hamdy FC. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23:2903-10.
17. Florl AR, Loewer R, Schmitz-Dräger BJ, Schulz WA. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinoma. Br J Cancer 1999; 80:1312-21.
18. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002; 21:5400-13.
19. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005; 83:296-321.
20. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003; 282:48-57.
21. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 2004; 23:3541-9.
22. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M. DNA methylation in serum of breast cancer patients: An independent prognostic marker. Cancer Res 2003; 63:7641-5.
23. Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000; 80:1513-22.
24. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, de Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91:540-52.
25. Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg RC, Klopocki E, Dahl E, Wild P, Blaszyk H, Sauter G, Simon R, Schmitt R, Zaak D, Hofstaedter F, Rosenthal A, Baylin SB, Pilarsky C, Hartmann A. Deletions of chromosome 8p and loss of sFRP1 espression are progression markers auf papillary bladder cancer. Lab Invest 2004; 84:465-78.
26. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, Cocco A, Cheng L. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005; 11:6512-9.
27. Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S, Obermann EC, Hammerschmied C, Wieland WF, Knuechel R, Hartmann A. Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 2005; 47:58-63.
28. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, Pfeifer GP. The tumor suppressor RASSF1A in human carcinogenesis: An update. Histol Histopathol 2005; 20:645-63.
29. Marsit CJ, Karagas MR, Andrew A, Liu M, Danaee H, Schned AR, Nelson HH, Kelsey KT. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res 2005; 65:7081-5.
30. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005; 65:4218-27.
31. Wu XR. Urothelial tumorigenesis: A tale of different pathways. Nat Rev Cancer 2005; 5:713-25.
32. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006; 118, (in press).
33. Stoehr R, Krieg RC, Knuechel R, Hofstaedter F, Pilarsky C, Zaak D, Schmitt R, Hartmann A. No evidence of involvement of β-catenin and APC in urothelial carcinomas. Int J Oncol 2002; 20:905-11.
34. Thievessen I, Seifert HH, Swiatkowski S, Florl AR, Schulz WA. E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells. Br J Cancer 2003; 88:1932-8.
35. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene 2000; 19:3642-6.
36. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-22.
37. Joesting M, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 2005; 65:10423-30.
38. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, Laird PW. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61:3410-8.
39. Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM. TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 2000; 60:6236-42.
40. Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 2002; 62:351-355.
41. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6.
42. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000; 92:1303-7.
43. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93:691-9.
44. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-9.
45. Schumann H, Holtz J, Zerkowski HR, Hatzfeld M. Expresssion of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovascular Res 2000; 45:720-8.